Substance Abuse: Research and Treatment is a premier open-access journal published by SAGE Publications Ltd, focusing on the multifaceted aspects of substance use and its impact on mental health. Since its establishment in 2008, this journal has been dedicated to disseminating innovative research findings, case studies, and reviews that enhance understanding and treatment of substance-related disorders. With an impact factor that reflects its standing in the field, currently ranked in the Q2 category of Psychiatry and Mental Health, Substance Abuse: Research and Treatment strives to foster interdisciplinary dialogue among researchers, practitioners, and students. By making its content freely accessible, the journal encourages widespread engagement and application of evidence-based practices to mitigate substance abuse issues. The journal’s diverse global perspectives make it a vital resource for anyone invested in advancing knowledge and improving treatment outcomes in this critical area of public health.

The Journal of Substance Use is a vital resource for researchers, professionals, and students in the fields of health and social sciences, published by Taylor & Francis Inc.. With an ISSN of 1465-9891 and E-ISSN of 1475-9942, this journal has been at the forefront of substance use research since its inception in 1996 and continues to provide a platform for the dissemination of innovative findings and critical analysis up to the year 2024. Ranking in the Q3 category for both Health (Social Science) and Medicine (Miscellaneous) in the 2023 quartiles, the journal encapsulates a broad spectrum of issues related to substance use, including addiction, intervention strategies, and policy implications. Although not an open-access journal, it remains accessible to a wide audience. With its substantial role in enhancing understanding and addressing the multi-faceted challenges of substance use, the Journal of Substance Use is essential for all stakeholders aiming to contribute to research and practice in this crucial area.

JOURNAL OF ADDICTIVE DISEASES, published by ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD, serves as a pivotal platform for researchers, clinicians, and students in the realms of clinical psychology, psychiatry, and addiction studies. With a distinguished history dating back to its inception in 1991, this journal spans critical research developments with its current scope covering converged years from 2018 to 2024, ensuring a robust repository of knowledge. Notably, it holds a respectable impact factor and is categorized in Q2 quartiles across several disciplines including Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health for 2023, reflecting its impactful contributions to the scientific community. Despite the journal not currently offering Open Access, it remains highly ranked, occupying positions in the top percentiles of Scopus rankings. This journal emphasizes the importance of disseminating high-quality research focused on addictive behaviors and diseases, thereby addressing vital clinical and public health challenges.

Addicta - The Turkish Journal on Addictions, published by the esteemed Turkish Green Crescent Society, is an open access journal dedicated to advancing the understanding of addictions and their implications on mental health. Since its inception in 2019, this journal has become a significant platform for interdisciplinary research, focusing on the biological, psychological, and sociocultural aspects of addiction. With a focus on both empirical studies and theoretical discussions, Addicta seeks to foster a greater understanding of addiction as a complex phenomenon, facilitating knowledge sharing among researchers, practitioners, and policymakers. The journal has achieved notable rankings, residing in the Q4 category in Biological Psychiatry and Psychiatry and Mental Health, and Q3 in miscellaneous Psychology, marking its growing impact in the field. Accessing its content is completely free, making important research accessible to a broader audience. Based in Turkey, Addicta provides a vital resource for those interested in the nuances of addiction research, promoting innovative solutions and fostering collaboration across disciplines.

Substance Abuse Treatment, Prevention, and Policy is a premier open access journal published by BMC, dedicated to advancing the understanding and improvement of substance abuse treatment and prevention strategies. Since its inception in 2006, this journal has established itself as a significant resource in the fields of Health Policy and Psychiatry and Mental Health, proudly maintaining a strong reputation reflected in its 2023 Scopus rankings, which place it in the top quartiles of these categories. With an impactful focus on policy implications and evidence-based practices, the journal's comprehensive coverage supports the sharing of innovative research and perspectives aimed at mitigating substance abuse challenges worldwide. Open access since its launch, it ensures that vital research is readily available to researchers, practitioners, and students alike, facilitating collaboration and discourse in this critical area of public health. Its commitment to high-quality research is underscored by its rankings within the 78th percentile for Health Policy and 66th percentile for Psychiatry and Mental Health, highlighting its influence and relevance in addressing pressing issues in substance misuse.

Welcome to the Journal of Addiction Medicine, a premier academic resource devoted to the field of addiction studies, published by LIPPINCOTT WILLIAMS & WILKINS. Since its inception in 2007, this esteemed journal has become a leader in disseminating groundbreaking research, with impressive rankings in the Q1 quartile across key disciplines such as Medicine (Miscellaneous), Pharmacology (Medical), and Psychiatry and Mental Health, reflecting its significance in the scholarly community. With an ISSN of 1932-0620 and an E-ISSN of 1935-3227, it caters to a diverse audience of researchers, clinicians, and students seeking to expand their understanding of addiction medicine. The journal's articles are primarily published in a non-open access format, ensuring high-quality research is accessible through institutional subscriptions. With a Scopus ranking that positions it within the top tiers of several relevant categories, the Journal of Addiction Medicine is essential for anyone committed to advancing knowledge in the field and addressing the complexities surrounding addiction.

Alkoholizm i Narkomania - Alcoholism and Drug Addiction is a prominent peer-reviewed journal published by the Institute of Psychiatry and Neurology, Department of Studies on Alcoholism in Warsaw, Poland. Renowned for its commitment to advancing the fields of addiction research and mental health, this journal disseminates critical findings regarding the prevention, treatment, and societal implications of alcoholism and drug addiction. Since becoming Open Access in 2017, it ensures that researchers, professionals, and students from across the globe have unrestricted access to valuable resources and emerging studies within this vital area of public health. The journal emphasizes innovative methodologies and interdisciplinary approaches, inviting contributions that explore the complex interplay of psychological, social, and biological factors influencing addiction. By fostering a collaborative and inclusive scholarly community, Alkoholizm i Narkomania aims to contribute significantly to the understanding and resolution of addiction-related challenges worldwide.

American Journal of Drug and Alcohol Abuse is a highly regarded publication in the field of substance abuse research, published by Taylor & Francis Inc. With its inception in 1974, this journal has become an essential resource for scholars and practitioners interested in clinical psychology, psychiatry, and the multifaceted issues surrounding drug and alcohol use. It holds a notable Q2 ranking in Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health, emphasizing its impact and relevance in these domains. The journal's 2023 Scopus rankings further highlight its standing, placing it in the top quartile of publications with established readership and citation metrics. Researchers and students can benefit from its comprehensive articles that delve into the complexities of substance use, treatment methodologies, and the socio-psychological underpinnings of addiction. Whether you seek to access cutting-edge studies or contribute to ongoing discourse in the field, the American Journal of Drug and Alcohol Abuse serves as a vital hub for knowledge dissemination and scholarly engagement.

Substance Abuse is a premier scholarly journal published by SAGE Publications Inc, dedicated to advancing the understanding and treatment of substance use disorders. With an established presence from 1995 to 2023, the journal boasts an impressive Q1 ranking in both Medicine (miscellaneous) and Psychiatry and Mental Health, positioning it among the top tier of academic publications in these fields. Researchers and professionals will find its articles, which are grounded in rigorous empirical studies and innovative interventions, essential for addressing the complex and multifaceted nature of substance abuse. Although not an open access publication, Substance Abuse maintains a commitment to sharing valuable insights and findings, making it a vital resource for those looking to enhance their knowledge and practice. Located in Thousand Oaks, CA, this journal serves as a critical forum for international dialogue and research dissemination, ensuring that current trends and challenges in substance use are thoughtfully examined and discussed within the academic community.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.